|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.5500 - 0.6300|
|52 Week Range||0.2100 - 0.7400|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
LAS VEGAS, Dec. 13, 2017 /PR Newswire/ -- GB Sciences, Inc. (GBLX) is proud to announce its development of a cannabis strain that has an extremely high THC concentration, and also has a specifically-defined terpene profile, meaning that this potent strain may have significant medical benefits. The plant produced a THC-a content of 35.119%, as well as β-myrcene levels of 2.18% and β-caryophyllene levels of 1.01%, as tested by independent lab Digipath Labs, Inc. in Las Vegas. This strain is the result of an ongoing research project and is one of many tangible results of the coordination of the three operating units--- Life Sciences, Tissue Propagation, and Cultivation Labs. GB Sciences is a fully integrated cannabis company with three complementary operating units.
GB Sciences: Develops Extremely High THC Content Cannabis Strain With Maximized Terpene Levels To Increase Medical Benefits
Phoenix, AZ, Dec. 12, 2017-- Uptick Newswire is the sole producer of the Uptick Network“ Stock Day” Podcast and after airing back in January 2016 CEO and host Everett Jolly has interviewed hundreds of ...
SLTK products may be improving yield and production for cannabis cultivators, by as much as 2x the industry norm, according to one public company. As a result, revenue could be set to take off in 2018, ...
LAS VEGAS, Dec. 5, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX) explains that 100% of the mother plants (a plant that in its vegetative state does not produce flowers but only branches and leaves) in their Las Vegas cultivation facility are now products of the GB Sciences tissue propagation initiative. In light of the popular belief that commercial tissue propagation is an 'urban myth' in the Cannabis world, this announcement is a true breakthrough. "We began the program in 2014 as a one-man project," said Dr. Ulrich Reimann-Philipp, Chief Botanist at GB Sciences.
GB Sciences Exceeds Its Gross Revenue Projections for October, Doubles the Industry Average Yield Per Active Flower Light
LAS VEGAS, Nov. 15, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces that it has exceeded the October gross revenue projection of $500K from the sale of premium flower by 2%. The GB Sciences cultivation facility has 180 active flower lights for plant cultivation and grows in a clean room-like environment.
Mr. Kevin Kuethe has been appointed COO of GB Sciences. The company is happy, the plants are happy, the customers are happy, and the shareholders should definitely be happy. LAS VEGAS, Nov. 13, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces that it has met the October gross revenue projection of $500K from the sale of premium flower.
Las Vegas, NV, Nov. 13, 2017-- GB Sciences, Inc. announces that it has met the October gross revenue projection of $500 K from the sale of premium flower. Gross sales projections for the month of November ...
Las Vegas, NV, Nov. 01, 2017--. GB Sciences, Inc. inducts a Scientific Advisory Board to provide oversight for product development within GB Sciences’ intellectual property portfolio, consisting of three ...
LAS VEGAS, Nov. 1, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX) inducts a Scientific Advisory Board to provide oversight for product development within GB Sciences' intellectual property portfolio, consisting of three original patent applications, one licensed patent application, and one licensed approved patent. The Scientific Advisory Board will be tasked with efficiently managing GB Sciences' resources while creating and testing their proprietary cannabis-based formulas.
This production agreement guarantees GB Sciences a set royalty on every gram produced and sold. LAS VEGAS, Oct. 30, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX) and Cura Cannabis Solutions (Cura) have executed a production agreement to produce high quality cannabis oils and related products utilizing the GB Sciences production license operated by the GB Sciences' Cultivation Labs™.
GB Sciences recorded unaudited sales of approximately $320,000 in the three months ended 9/30/17. The company is operating at 200 grow lights, which is only 30% of its expected final capacity after build out is completed. The company is expected to open its production facility in late November or early December of 2017.
LAS VEGAS, Oct. 17, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has obtained the exclusive worldwide license to intellectual property covering a time-released cannabinoid formulation from the Universidad de Seville ("USE"), the Universidad de Cadiz ("UCA"), and the Centro de Investigación Biomédica en Red de Salud Mental ("CIBERSAM"). "GB Sciences recognizes the ineffectiveness of current delivery methods for cannabis-based medicines (i.e., smoking, vaping, sublingual, and ingestion), and therefore licensed this innovative new cannabinoid nanotechnology from the University of Seville," explained Dr. Andrea Small-Howard, Chief Science Officer.
LAS VEGAS, Oct. 10, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has entered into a Contract Research Agreement with the Universidad de Sevilla ("USE") to develop a time-released version of GB Sciences' proprietary, THC-free, myrcene-based chronic pain formulations. GB Sciences has identified USE as having top-notch nanotechnology experts, excellent research facilities, and state-of-the art scientific equipment. The group working with GB Sciences on this important project is headed by Dr. Mercedes Fernández Arévalo and Dr. Lucia Martin Banderas.
LAS VEGAS , Sept. 18, 2017 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) announces that Louisiana State University ( LSU ) AgCenter has posted comments on the recently finalized agreement between GB ...
LAS VEGAS , Sept. 18, 2017 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) announces that Louisiana State University ( LSU ) AgCenter has signed their agreement with GB Sciences Louisiana, LLC, a wholly-owned ...
LAS VEGAS, Aug. 2, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is proud to announce an agreement with the Los Coyotes Band of Cahuilla and Cupeno Indians (Los Coyotes) for the purposes of establishing cannabis operations on the tribe's lands located near Warner Springs, California. This is the first time a publicly traded US cannabis cultivation company and a federally recognized Native American tribe have announced a commercial cannabis venture in California. GB Sciences will construct facilities on designated areas of tribal land for the business of cultivation, manufacturing and other commercial cannabis activities.
LAS VEGAS, July 17, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has signed a Consulting Services Agreement with Worldwide Clinical Trials, Inc. to evaluate the company's intellectual property portfolio and to assist with pre-IND planning for its proprietary cannabis-based formulations. Dr. Murphy has participated in the IND application process for multiple small molecules and biologics with 19 therapeutic targets, across five divisions of the FDA. Dr. Murphy was also the Clinical Research and Excellence (CARE) Lifetime Achievement Award recipient for 2017.
GB Sciences Will Bring Medical-Grade Cannabis to the Recreational Use Market by Introducing Cultivation Labs™ Branded Products LAS VEGAS , July 10, 2017 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) ...
63 pounds were sold as premium flower, with 66.5 pounds held back for conversion to medical grade cannabis oil. LAS VEGAS, July 5, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has harvested its first crop and sold 63 pounds of premium flower while holding back 66.5 pounds for conversion to medical grade oil. GB Sciences has spent the past year-and-a-half building what has been called by many industry professionals 'the cleanest grow facility in the business'.
The LSU Agricultural Center has one of the only two licenses granted by the State of Louisiana to cultivate, distribute and sell medical cannabis. In addition, GB Sciences will have first rights to commercialize any inventions or discoveries of the research center. LAS VEGAS, June 26, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX) secures bid to Louisiana State University (LSU) and receives authorization from the LSU Board of Supervisors to proceed with contract negotiations to act as the LSU Agricultural Center's (AgCenter) licensed operator of their medical cannabis production facility as outlined in the Alison Neustrom Act (hereinafter referred to as the "Act"). The secured bid will enable GB Sciences to be the sole vendor of cannabis and extracted cannabis compounds on behalf of LSU for the patients of Louisiana. The agricultural centers at LSU and Southern University have the only two licenses granted by the State of Louisiana to cultivate, distribute, and sell medical cannabis.